title: Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version.
abstract: Diagnostic and treatment strategies for gastrointestinal stromal tumors (GISTs) have evolved greatly since the introduction of molecularly targeted therapies. Although several clinical practice guidelines are extant, such as those published by the National Comprehensive Cancer Network and the European Society of Medical Oncology, it is not clear as to whether these are appropriate for clinical practice in Japan. Therefore, clinical practice guidelines for the optimal diagnosis and treatment of GIST tailored for the Japanese situation have often been requested. For this reason, the Japanese Clinical Practice Guideline for GIST was proposed by the GIST Guideline Subcommittee, with the official approval of the Clinical Practice Guidelines Committee for Cancer of the Japan Society of Clinical Oncology (JSCO), and was published after assessment by the Guideline Evaluation Committee of JSCO. The GIST Guideline Subcommittee consists of members from JSCO, the Japanese Gastric Cancer Association (JGCA), and the Japanese Study Group on GIST, with the official approval of these organizations. The GIST Guideline Subcommittee is not influenced by any other organizations or third parties. Revision of the guideline may be done periodically, with the approval of the GIST Guideline Subcommittee, either every 3 years or when important new evidence that might alter the optimal diagnosis and treatment of GIST emerges. Here we present the English version of the Japanese Clinical Practice Guideline for GIST prepared by the GIST Guideline Subcommittee.
authors.affiliation: Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. toshin@surg1.med.osaka-u.ac.jp
authors.forename: Toshirou
authors.initials: T
authors.lastname: Nishida
authors.forename: Seiichi
authors.initials: S
authors.lastname: Hirota
authors.forename: Akio
authors.initials: A
authors.lastname: Yanagisawa
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Sugino
authors.forename: Manabu
authors.initials: M
authors.lastname: Minami
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Yamamura
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Otani
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Shimada
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Takahashi
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kubota
mesh_terms: D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D003952:Diagnostic Imaging; D019008:Drug Resistance, Neoplasm; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis* / Q000601:surgery / Q000628:therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D009154:Mutation; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D010879:Piperazines / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit